anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Non-immunogenic biocompatible macromolecular sheet composition are formed from a cellulosic membrane, a binding moiety having a plurality of functional groups, and a glycosaminoglycan (GAG). The binding moiety has the formula of R1-X-R2 wherein R1 and R2 are the same or different. The binding moiety, through functional groups binds the cellulosic membrane with the glycosaminoglycan. R1 is covalently bound to a carbon or an oxygen of the cellulosic membrane. R2 is covalently bound to a carbon, an oxygen, or a nitrogen of the glycosaminoglycan. The binding moiety can be bis-oxyrane, butanediol-diglycidyl ether (BDE), or divinyl sulfone. The cellulosic membrane can be a cellulosic membrane, partially acetylated cellulose and a copolymer of hydroxyethyl-methacrylate with methyl methacrylate, abbreviated as HEMA-MMA. The non-immunogenic biocompatible macromolecular sheet composition can be formed into a pouch to encapsulate cells, tissues, pharmaceuticals, or biological metabolic products. In addition, the non-immunogenic biocompatible macromolecular sheet composition can also be used as a skin graft or a skin substitute. Further, these non-immunogenic biocompatible macromolecular sheet composition can also be used as a surface to culture cells in vitro.
In a pharmaceutical composition containing at least one alkali-sensitive active substance and an effervescent system, the active substance is embedded in at least one of the following compounds: an edible organic acid, a higher alcohol, an hydrocolloid, a long-chain polyvinyl pyrrolidone, and is preferably coated with at least one of said compounds. The carbonate component is preferably also embedded in at least one edible organic acid and preferably coated by the same or another acid. The contact zone between active substance and effervescent system must have a pH value of maximum 4.5. Both effervescent system and active substance particles thus embedded and if required coated may be applied on a substrate made of crystals of the same of another acid. The mixture is preferably pressed into tablets. The acid used for embedding or coating may comprise 0.1 to 3 mg ethylene diamine tetra-acetic acid per tablet.
Assistive technology (AT) with context-aware computing and artificial intelligence capabilities can be applied to address cognitive and communication impairments experienced by persons with dementia (PwD). This paper aims to provide an overview of current literature regarding some characteristics of intelligent assistive technology devices (IATDs) for cognitive and communicative impairments of PwD. It also aims to identify the areas of impairment addressed by these IATDs.A multi-faceted systematic search strategy yielded records. Predefined criteria were applied for inclusion and data extraction. Thereafter data was thematically analysed and synthesised. This review demonstrates that almost all of the research involving IATDs has focused on cognitive impairments of PwD and has not yet evolved past the conceptual or prototype stages of development. Summaries of commercially available IATDs for PwD and relevant prototypes are provided at the end of this review.This research concluded that IATDs for PwD targeting cognition and communication problems primarily focus on social robots, and that they address cognitive impairments of attention, affect, and social-pragmatic communicative impairments. Future research endeavours concerning AT for PwD should explore collaboration between computer engineering and health practitioners to address the identified gaps. This may contribute to the available information for evidence-based decision making for PwD.
Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks (Eskandari, Keshavarz, \& Jahdi, 2010). Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks (Djordjevic, 2010 ). The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it (Arabin, 2002). It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements (Campbell-Yeo, Fernandes, \& Johnston, 2011).
A competitor for human Immunoglobulin E (IgE) comprises a polypeptide which has a core sequence of seventy-six amino acids which is shown, together with the corresponding DNA sequence coding therefor, in FIG. 2. This amino acid sequence, numbered 1 to 76, corresponds to amino acids 301 to 376 of the epsilon heavy cain of IgE. The polypeptide may also include additional short sequences at the beginning and/or end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to bind compete with native IgE for the high-affinity receptor sites on human cells. The polypeptide is indicated for the treatment of Type I hypersensitivity reactions such as hay fever. The polypeptide may be produced synthetically or by expression from Escherichia coli containing a plasmid having a DNA segment coding for the polypeptide.
Mutations in voltage-gated sodium (Nav) channels, which are essential for generating and propagating action potentials, can lead to serious neurological disorders, such as epilepsy. However, disease-causing Nav channel mutations do not always result in severe symptoms, suggesting that the disease conditions are significantly affected by other genetic factors and various environmental exposures, collectively known as the "exposome". Notably, recent research emphasizes the pivotal role of commensal bacteria in neural development and function. Although these bacteria typically benefit the nervous system under normal conditions, their impact during pathological states remains largely unknown. Here, we investigated the influence of commensal microbes on seizure-like phenotypes exhibited by paraShu-a gain-of-function mutant of the Drosophila Nav channel gene, paralytic. Remarkably, the elimination of endogenous bacteria considerably ameliorated neurological impairments in paraShu. Consistently, reintroducing bacteria, specifically from the Lactobacillus or Acetobacter genera, heightened the phenotypic severity in the bacteria-deprived mutants. These findings posit that particular native bacteria contribute to the severity of seizure-like phenotypes in paraShu. We further uncovered that treating paraShu with antibiotics boosted Nrf2 signaling in the gut, and that global Nrf2 activation mirrored the effects of removing bacteria from paraShu. This raises the possibility that the removal of commensal bacteria suppresses the seizure-like manifestations through augmented antioxidant responses. Since bacterial removal during development was critical for suppression of adult paraShu phenotypes, our research sets the stage for subsequent studies, aiming to elucidate the interplay between commensal bacteria and the developing nervous system in conditions predisposed to the hyperexcitable nervous system.
Compositions, methods, and formulations for delivering 5-HT 3  antagonists across the oral mucosa are described. In some variations, the described compositions comprise at least one 5-HT 3  antagonist, which is at least partly in an ionized form, and a buffer system. The buffer system generally comprises at least two different buffering agents and is capable of changing the pH of saliva from an arbitrary initial pH to a predetermined final pH, and of sustaining the final pH for a period of time. The predetermined final pH favors substantially complete conversion of the ionized form to the un-ionized form. In other variations, the described compositions comprise a 5-HT 3  antagonist, at least partly in an un-ionized form, and a buffer system. In these variations, the buffer system is capable of providing an adjusted salival pH such that the 5-HT 3  antagonist remains in its un-ionized form. Dissolving tablets are also described.
In the conventional group, participants will receive a FiO2 aiming to maintain a SpO2 equal or major than 98 percentage, accepting an upper limit of PaO2 of 150 mmHg and a lower limit of 70 mmHg. The use of a FiO2 of less than 0.3 whilst ventilated is discouraged. According to standard Intensive Care Unit practice, control patients will receive a FiO2 of 1.0 during endotracheal intubation manoeuvre, airway suction or in-hospital transfers.
The present invention relates to peptides that specifically bind to neuropilin 1(NRP1) only and not neuropilin 2(NRP 2); a fusion protein, small molecule drug, nanoparticle or liposome fused to the peptide; and a pharmaceutical composition comprising the peptide for treating or preventing cancer or angiogenesis-related diseases, and a composition comprising the peptide for diagnosing cancer or angiogenesis-related diseases. In addition, the present invention provides polynucleotides for encoding peptides that specifically bind to NRP 1. Furthermore, the present invention relates to a method for screening peptides that specifically bind to NRP 1. The antibody heavy chain constant region fused to the peptide of the present invention that specifically binds to NRP1 has the characteristic of specifically binding to NRP1 and, therefore, when administered in vivo, selectively accumulates on tumor tissue, widens the intercellular space between tumor vascular endothelial cells, promotes extravasation, and increases tumor tissue penetration. Furthermore, the antibody heavy chain constant region fused to a peptide of the present invention that specifically binds to NRP1 inhibits Vascular Endothelial Growth Factor (VEGF) binding to neuropilin 1, and thus has the ability to inhibit angiogenesis in tumor tissues. Thus, the antibody heavy chain constant region fused to the peptide of the invention exhibits in vivo tumor suppression activity.
To elucidate the specific and shared genetic background of schizophrenia (SCZ) and bipolar disorder (BPD), this study explored the association of polygenic liabilities for SCZ and BPD with educational attainment and cognitive aging. Among 106,806 unrelated community participants from the Taiwan Biobank, we calculated the polygenic risk score (PRS) for SCZ (PRSSCZ) and BPD (PRSBPD), shared PRS between SCZ and BPD (PRSSCZ+BPD), and SCZ-specific PRS (PRSSCZvsBPD). Based on the sign-concordance of the susceptibility variants with SCZ/BPD, PRSSCZ was split into PRSSCZ_concordant/PRSSCZ_discordant, and PRSBPD was split into PRSBPD_concordant/PRSBPD_discordant. Ordinal logistic regression models were used to estimate the association with educational attainment. Linear regression models were used to estimate the associations with cognitive aging (n = 27,005), measured by the Mini-Mental State Examination (MMSE), and with MMSE change (n = 6194 with mean follow-up duration of 3.9 y) in individuals aged≥ 60 years. PRSSCZ, PRSBPD, and PRSSCZ+BPD were positively associated with educational attainment, whereas PRSSCZvsBPD was negatively associated with educational attainment. PRSSCZ was negatively associated with MMSE, while PRSBPD was positively associated with MMSE. The concordant and discordant parts of polygenic liabilities have contrasting association, PRSSCZ_concordant and PRSBPD_concordant mainly determined these effects mentioned above. PRSSCZvsBPD predicted decreases in the MMSE scores. Using a large collection of community samples, this study provided evidence for the contrasting effects of polygenic architecture in SCZ and BPD on educational attainment and cognitive aging and suggested that SCZ and BPD were not genetically homogeneous.
Persistent post-surgical pain (PPSP) is defined as pain which continues after a surgical operation in a significant form for at least three months (and is not related to pre-existing painful conditions). PPSP is a common, under-recognised, and important clinical problem which affects millions of patients worldwide. Preventative measures which are currently available include the selection of a minimally invasive surgical technique and an aggressive multimodal perioperative analgesic regimen. More recently, a role for the gut microbiota in pain modulation has become increasingly apparent. This study aims to investigate any relationship between the gut microbiota and PPSP. A prospective observational study of 68 female adult patients undergoing surgery for management of breast cancer was carried out. Stool samples from 45 of these patients were obtained to analyse the composition of the gut microbiota. Measures of pain and state-trait anxiety were also taken to investigate further dimensions in any relationship between the gut microbiota and PPSP. At 12 weeks postoperatively, 21 patients (51.2%) did not have any pain and 20 patients (48.8%) reported feeling pain that persisted at that time. Analysis of the gut microbiota revealed significantly lower alpha diversity (using three measures) in those patients reporting severe pain at the 60 min post-operative and the 12 weeks post-operative timepoints. A cluster of taxa represented by Bifidobacterium longum, and Faecalibacterium prausnitzii was closely associated with those individuals reporting no pain at 12 weeks postoperatively, while Megamonas hypermegale, Bacteroides pectinophilus, Ruminococcus bromii, and Roseburia hominis clustered relatively closely in the group of patients fulfilling the criteria for persistent post-operative pain. We report for the first time specific associations between the gut microbiota composition and the presence or absence of PPSP. This may provide further insights into mechanisms behind the role of the gut microbiota in the development of PPSP and could inform future treatment strategies.
Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
Asian patients who are older than 16 years of age and have HBeAg-positive chronic hepatitis B and good liver function will be entered in this study. Qualified patients also have positive hepatitis B surface antigen (HBsAg) for at least 24 weeks before screening, evidence of chronic hepatitis on a baseline liver-biopsy sample obtained within 52 weeks before entry, evidence of HBV DNA by any commercial tests at least 4 weeks before screening, an high HBV DNA level (at least 20,000 IU/mL) at screening, and a high serum ALT level (1.0 to 5.0 times the upper limit of normal) at screening.

This study involves experimental use of an approved drug (Prednisolone) on chronic hepatitis B patients. Patients will be involved in the study for up to 96 weeks from enrollment. There is no external sponsor, commercial sponsor nor federal agency on this study. The study will be conducted only at Maimonides Medical Center, its GI clinic and faculty practice. About 40 subjects will be involved in the study overall. All the subjects will be filled up locally.
Oral and nasal disinfection, a simple method with the application of commonly used antiseptic agents is frequently performed in the otolaryngology and dental practice. The ability to deactivate viral particles with a good safety profile may be an important benefit in the control of viral proliferation and shedding. Actually, multiple anti-septic agents demonstrated virucidal properties against SARS-CoV-2 in several in vitro studies. Among these, Povidone-Iodine (PVP-I), common usage in otolaryngology operation and topical therapy, showed high virucidal properties (0.45% PVP-I, throat spray, 4-log drop in viral load) and of great safety. There is also evidence that topical usage of saline can decrease the severity of upper respiratory tract infection. In addition, carrageenan, a sulphated polysaccharide purified from red marine algae, had shown efficacy in inhibiting multiple viruses, including in vitro studies of SARS-CoV-2. Some randomized controlled trials had also shown their abilities in improving patients' symptoms with a good safety profile. Multiple international organizations are conducting relating randomized clinical trials to evaluate whether the topical anti-septic improves clinical outcomes after early SARS-CoV-2 infection. The added value of topical antiseptic agents may be beneficial in improving symptoms, reducing viral load and alleviating the rate of disease progression. Due to relatively low risk, well-toleration to the general population, and highly available characteristics, the potential benefits of these agents deserve more attention.

The goal of this study is to investigate the changes in clinical symptoms and sequential laboratory data in confirmed COVID-19 adult patients at the early disease stage. By applying topical anti-septic which is frequently used in otolaryngology procedures, the investigators will evaluate the impact of this intervention on the symptoms, viral load and the rate of disease progression. During the global pandemic period, an effective and highly available method once be identified, it will reduce the risk of disease transmission and lower the medical burden.
The sham character is ensured by the stimulation time, once the device is programmed to turn off 30 seconds after the beginning of stimulation. The current is switched in ascending ramp mode for 10 seconds until 2 mili ampere and a descending ramp similar also for 10 seconds will be used until the end of stimulation. The sham stimulation is commonly perceived by the patient as the actual treatment and all procedures for the application of the technique should be similar to those adopted for the active stimulation. Immediately after tDCS stimulation, the gait training consisting of a protocol based on sensory cues for 30 minutes is administered three times a week for four weeks. Sham stimulation will be held for 30 seconds in order to mimic the perceived lowering effect of ramp current.
Sjogren's syndrome (SS) is a systemic autoimmune disease that predominantly affects women. SS is characterized by lymphocytic infiltration of lacrimal and salivary glands leading to secretory function loss, and the symptoms of dry eyes and dry mouth. After bone marrow transplantation, most patients with chronic graft versus host disease (GVHD) develop symptoms of oral dryness and salivary gland lymphocytic infiltrates indistinguishable from SS. Thalidomide has not been studied as a treatment for Sjogren's syndrome, but pilot studies suggest that it may be beneficial in the treatment of a number of autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and various skin disorders, as well as in the treatment of chronic graft versus host disease. Major adverse effects of thalidomide include teratogenicity, neuropathy and sedation. The study is a 12 week randomized, double-blinded, pilot clinical trial designed to screen for potential efficacy and to evaluate the safety and potential adverse effects of 300 mg thalidomide daily compared with placebo in 28 patients with primary SS (PSS).
Graded exposure therapy consists of set of exercises, performed for 3 weeks with 3 sessions per week. Each exercise protocol has 5 to 10 repetitions per day.
A scan area setting unit of an exemplary ophthalmic apparatus sets a scan area in a region passing through an iris outer edge. A first scan controller controls an OCT optical system to apply an OCT scan to the scan area. An image quality evaluating unit calculates an image quality evaluation value of an image from the OCT scan. A corner angle image detecting unit analyzes the image to detect a corner angle image. A position judging unit judges whether the corner angle image is located within a first area in an image frame. A second scan controller controls the OCT optical system to apply an OCT scan of a predetermined pattern to the anterior segment, if the image quality evaluation value is equal to or greater than a threshold and the corner angle image is located within the first area.
Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
BACKGROUND: Ischemic stroke is a medical emergency for which effective treatment remains inadequate. Curcumin (Cur) is a natural polyphenolic compound that is regarded as a potent neuroprotective agent. Compared to synthetic pharmaceuticals, Cur possesses minimal side effects and exhibits multiple mechanisms of action, offering significant advantages in the treatment of ischemic stroke. However, drawbacks such as poor water solubility and transmembrane permeability limit the efficacy of Cur. In recent years, nano-delivery systems have attracted great interest in the field of stroke therapy as an effective method to improve drug solubility and cross the blood-brain barrier (BBB).
METHODS: In this study, a novel nanomedicine (Cur@GAR NPs) for ischemic stroke treatment was developed based on Cur-loaded gelatin nanoparticles (Cur@Gel NPs) that were then functionalized and modified with rabies virus glycoprotein (RVG29) to target brain tissue. The stability, antimicrobial properties, antioxidant properties, neuroprotective effects, neuronal cell uptake, and biocompatibility of Cur@GAR NPs were investigated in vitro. The in vivo therapeutic effect of Cur@GAR NPs on ischemic stroke was investigated in a middle cerebral artery occlusion (MCAO) rat model using the Morris water maze test and the open field test, and the potential mechanism of action was further investigated by histological analysis.
RESULTS: The resulting Cur@GAR NPs improved the solubility of Cur and exhibited good dispersion. In vitro studies have shown that Cur@GAR NPs exhibit great antimicrobial properties, antioxidant properties and intracellular reactive oxygen species (ROS) protection. Notably, RVG29 significantly enhanced the uptake of Cur@GAR NPs by SH-SY5Y cells. Furthermore, in vivo studies verified the role of Cur@GAR NPs in reducing nerve damage and supporting neurological recovery. In the MCAO rat model, Cur@GAR NPs significantly attenuated neuroinflammation, reduced neuronal apoptosis and restored behavioral functions to a great extent.
CONCLUSION: Together these findings implied that Cur@GAR NPs could provide a novel and promising approach for effective ischemic stroke treatment.
PURPOSE:To provide a cosmetic for skin protection, having excellent safety and stability, and containing an interlattice compound of a montmorillonite-group clay mineral and an ultraviolet absorbent. CONSTITUTION:An ultraviolet absorbent (e.g. ethyl p-aminobenzoate, menthyl salicylate, etc.; preferably those soluble in oil or hardly soluble in water) is used as it is when the absorbent is liquid, or used as a solution by dissolving in a proper solvent when it is not liquid. The absorbent is mixed with one or more clay minerals selected from montmorillonite-group clay minerals (e.g. montmorillonite, beidellite, nontronite, saponite, etc.) and water, and stirred with a high- speed stirrer such as homogenator, homomixer, etc. to effect the intrusion of the ultraviolet absorbent between the lattice layers. An ultraviolet absorbent composition composed of a transparent interlattice compound can be produced by this process. The amount of the ultraviolet absorbent is 0.001-0.005mol per 10g of the clay mineral.